Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2018-03-19 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
关于召开2017年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2017 Annual General Meeting (AGM) of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes information about the meeting time, location, agenda items to be voted on, voting procedures, and proxy forms. The content focuses on the organization and conduct of the AGM rather than the actual annual report or financial statements. It does not contain financial data or results but rather the meeting notice and related procedural information. Therefore, this document fits the category of AGM Information (AGM-R). The document length (over 10,000 characters) and detailed content confirm it is the meeting notice itself, not just an announcement of a report publication.
2018-03-19 Chinese
第六届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the 6th Board of Directors of Beijing Shuanglu Pharmaceutical Co., Ltd. It includes approvals of the 2017 annual general manager work report, board work report, financial statements, profit distribution plan, annual report and summary, internal control evaluation report, social responsibility report, audit firm appointment, related party transactions, short-term investment plan, nomination of new board members, establishment of a charitable foundation, and the scheduling of the 2017 annual shareholders meeting. The document is a formal board meeting resolution announcement, not the full annual report itself. It references the full 2017 annual report and other reports being available on the designated disclosure website and newspapers, indicating this document is a meeting resolution announcement rather than the report. The document length is 4561 characters, which is relatively short and consistent with a meeting resolution announcement. Therefore, this document fits best under Board/Management Information (MANG) as it announces board meeting decisions and management reports approval, including board member nominations and other governance matters.
2018-03-19 Chinese
关于举行2017年年度报告网上业绩说明会的通知
AGM Information Classification · 95% confidence The document is a notice about holding an online performance explanation meeting for the 2017 annual report. It invites investors to participate in the event and lists the attendees. The document does not contain the actual annual report or financial data but is an announcement related to the annual report meeting. The document length is short (505 characters), and it serves as a notification rather than the report itself. According to the classification rules, such a document is best classified as AGM Information (AGM-R) because it relates to the Annual General Meeting or annual report presentation event.
2018-03-19 Chinese
独立董事魏素艳2017年度述职报告
Board/Management Information Classification · 95% confidence The document is a detailed annual report by an independent director of Beijing Shuanglu Pharmaceutical Co., Ltd. for the year 2017. It includes the director's attendance at board meetings, opinions on profit distribution, internal control evaluation, audit firm appointment, related party transactions, investment decisions, and governance oversight. The content is a comprehensive management and governance report related to the company's annual activities and internal controls, not a simple announcement or certification. It is not a full annual report (10-K) but rather a management-related report focusing on the independent director's duties and opinions for the year. This fits best under Board/Management Information (MANG) as it relates to board activities and management oversight by an independent director.
2018-03-19 Chinese
控股股东及其他关联方资金占用情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special explanation report regarding the use of funds by controlling shareholders and related parties of Beijing SL Pharmaceutical Co., Ltd. It is issued by Da Hua Certified Public Accountants and references the 2017 fiscal year ending December 31, 2017. The document includes a summary table of fund occupation by related parties and is prepared in accordance with Chinese regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is not a full annual report or interim report but a standalone audit-related disclosure focusing on related party transactions and fund occupation. The document contains detailed financial data related to these transactions and is signed by the accounting firm. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on a specific issue (related party fund occupation), not the full annual report or other types of filings. The document length is about 5009 characters, sufficient to contain substantive data and explanations, not just an announcement or certification. Therefore, the classification is AR with high confidence. FY 2017
2018-03-19 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes detailed information about the internal control evaluation of Beijing SL Pharmaceutical Co., Ltd. for the year ended December 31, 2017. It is issued by a certified public accounting firm and contains an auditor's opinion on the effectiveness of internal controls related to financial reporting. The document includes detailed descriptions of the internal control environment, risk assessment, control activities, information and communication, and internal supervision. It also discusses the standards for identifying internal control deficiencies and the company's evaluation results, concluding that no material deficiencies were found. This type of document is a standalone audit-related report focusing on internal control effectiveness, not a full annual report or financial statement. It fits the definition of an Audit Report / Information (AR) as it is a standalone audit report on internal controls, not the full annual report (10-K) or interim report (IR). The document length (13,025 characters) and content confirm it is a full report, not just an announcement or certification letter, so it is not RPA or RNS. Therefore, the correct classification is AR with high confidence. FY 2017
2018-03-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.